This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Renner, S. Articles by Lichtenstein, A. Search for Related Content PubMed PubMed Citation Articles by Renner, S. Articles by Lichtenstein, A.

Expression of BAX in Plasma Cell Dyscrasias¹

Departments of Medicine [A. L.] and Pathology [S. R.], Veterans Affairs West Los Angeles Hospital and University of California at Los Angeles Medical School, Los Angeles, California 90073; the Jonsson Comprehensive Cancer Center, Los Angeles, California 90073, Kaiser Permanente Hospital, Woodland Hills, California 91365 [J. W.]; and The Burnham Institute, La Jolla, California 92037 [S. K., M. K., J. C. R.]

Several studies demonstrate that the BCL-2 and BCL-XL antiapoptotic genes are variably expressed in plasma cells of patients with multiple myeloma (MM). However, the plasma cell expression of BAX protein, their major proapoptotic partner, has not been investigated. Our initial Western blot analysis of myeloma cell extracts also suggested patient variability in the expression of BAX, which was not altered by exposure to interleukin 6. To further investigate the significance of BAX expression, we performed immunohistochemistry on archival bone marrow biopsies and compared BAX staining to BCL-2 immunostaining. Expression was first evaluated in 104 patients with reactive plasmacytosis, monoclonal gammopathy of undetermined significance/smoldering MM, or active MM. An increase (P < 0.05) in expression of both BAX and BCL-2 was detected in MM patients compared with patients with reactive plasmacytosis. Patients with monoclonal gammopathy of undetermined significance/smoldering MM had intermediate values. For correlations with outcome, expression was assessed in 43 patients at diagnosis who were treated with melphalan and prednisone; 30 at diagnosis who were treated with vincristine, Adriamycin, and dexamethasone; and 29 at relapse who were treated with second-line therapy. There was no correlation between BAX or BCL-2 expression and response to chemotherapy or duration of response or between BCL-2 expression and survival. However, patients who demonstrated extremely low plasma cell BAX expression had significantly increased survival. This was true for patients initially treated with melphalan and prednisone or vincristine, Adriamycin, and dexamethasone, as well as patients studied at relapse. BAX expression did not correlate with expression of proliferating cell nuclear antigen used as a marker of proliferation. These data indicate a myeloma-specific increase in BAX expression in plasma cells and suggest that low BAX expression identifies a cohort of patients with long survival, which is not specifically associated with low proliferating cell nuclear antigen expression.

This article has been cited by other articles:

				S. Paneesha, K. Hawkins, F. Davies, L. Hooper, J. Starczynski, C. Pepper, G. Morgan, C. Fegan, and G. Pratt BAX UTR G (-248) A Polymorphism Has No Impact on Survival in Patients with Multiple Myeloma. Blood (ASH Annual Meeting Abstracts), November 16, 2006; 108(11): 5022 - 5022. [Abstract] [PDF]

				A. M. Evens, S. Prachand, B. Shi, M. Paniaqua, L. I. Gordon, and R. B. Gartenhaus Imexon-Induced Apoptosis in Multiple Myeloma Tumor Cells Is Caspase-8 Dependent Clin. Cancer Res., February 15, 2004; 10(4): 1481 - 1491. [Abstract] [Full Text] [PDF]